Certara Announces Expansion of Clinical Technology Collaboration with Merck

2025年7月8日

RADNOR, PA – 2025年7月8日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management. This agreement builds upon Merck’s existing technology collaboration with Certara to aid in regulatory submissions.

Reducing the time from data collection to validated, analysis-ready datasets has become more complex across drug development. Phase III clinical trials now average 3.6 million datapoints, a threefold increase over the last decade.¹ The Certara Pinnacle 21 platform is designed to solve the data standardization challenges of modern digital trials at scale.

To learn more about Pinnacle 21 Enterprise clinical data management and automation suite, please visit www.certara.com/pinnacle-21-enterprise-software/

¹ Tufts Center for the Study of Drug Development (CSDD) Impact Report November/December 2021